Skip to main content

Search Videos

Showing 37 - 48 of 106 results

Previous| 1... 3 | 4 | 5 ...9 |Next

Do you have any explanation for why liraglutide was associated a lower risk of hypoglycemia than in the control arm of the LEADER trial?

Do you have any explanation for why liraglutide was associated a lower risk of hypoglycemia than in the control arm of the LEADER trial?

How would deploy the fixed ratio combination agents in an obese patient who was not meeting HA1c target goals on metformin alone, or a second oral agent?

How would deploy the fixed ratio combination agents in an obese patient who was not meeting HA1c target goals on metformin alone, or a second oral agent?

In your mind what are the implications of the LEADER trial evaluating liraglutide in reducing CV outcomes?

In your mind what are the implications of the LEADER trial evaluating liraglutide in reducing CV outcomes?

Based on LEADER, what do you believe the implications are for the use of liraglutide to mitigate or stabilize diabetic nephropathy? What degree of CV event reduction was observed in patients with CKD?

Based on LEADER, what do you believe the implications are for the use of liraglutide to mitigate or stabilize diabetic nephropathy? What degree of CV event reduction was observed in patients with CKD?

Can you drill down into the results of LEADER, including primary end points and breakdown of MACE events? What did we learn about the dose of liraglutide required for CV outcome improvement?

Can you drill down into the results of LEADER, including primary end points and breakdown of MACE events? What did we learn about the dose of liraglutide required for CV outcome improvement?

Given the established use of metformin and SGLT2 inhibitors as oral foundation agents, where do you believe the GLP-1 RA/insulin combination regimens, which are injectable, are likely to play the most important role in guideline-directed care?

Given the established use of metformin and SGLT2 inhibitors as oral foundation agents, where do you believe the GLP-1 RA/insulin combination regimens, which are injectable, are likely to play the most important role in guideline-directed care?

What metabolic and hemodynamic parameters were affected most significantly in LEADER and what new information did we learn about the safety profile of liraglutide?

Based on clinical profiles and metabolic parameters, which patients with T2D are ideally suited for treatment with a fixed ratio, combination of insulin and a GLP-1 RA?

Based on clinical profiles and metabolic parameters, which patients with T2D are ideally suited for treatment with a fixed ratio, combination of insulin and a GLP-1 RA?

What are the withdrawal and regimen adherence rates with the GLP-1 RA/insulin regimens, and how do the fixed ratio combination formulations affect GI side effects sometimes encountered with GLP-1 RAs? Is the incidence of side effects lower?

What are the withdrawal and regimen adherence rates with the GLP-1 RA/insulin regimens, and how do the fixed ratio combination formulations affect GI side effects sometimes encountered with GLP-1 RAs? Is the incidence of side effects lower?

What are the clinical implications of the fact that liraglutide’s benefits were seen in a high risk population that was already on maximal therapy for CV risk reduction?

What are the clinical implications of the fact that liraglutide’s benefits were seen in a high risk population that was already on maximal therapy for CV risk reduction?

What level of HA1c reduction is achieved with the fixed ratio combination and how is the side effect profile of the GLP-1 RA affected by the combination formulation and the titration strategy it utilizes?

What did we learn about hypoglycemic risk from the LEADER trial as it relates to the GLP-1 RA evaluated?

What did we learn about hypoglycemic risk from the LEADER trial as it relates to the GLP-1 RA evaluated?

Showing 37 - 48 of 106 results

Previous| 1... 3 | 4 | 5 ...9 |Next